Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report)'s stock price gapped down prior to trading on Monday. The stock had previously closed at $3.92, but opened at $3.38. Aclaris Therapeutics shares last traded at $3.4640, with a volume of 2,287,360 shares trading hands.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on the stock. Canaccord Genuity Group boosted their price objective on shares of Aclaris Therapeutics from $10.00 to $13.00 and gave the company a "buy" rating in a report on Friday, October 30th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Wedbush reduced their price objective on Aclaris Therapeutics from $10.00 to $8.00 and set an "outperform" rating for the company in a research note on Wednesday, October 28th. Craig Hallum set a $9.00 price objective on shares of Aclaris Therapeutics in a research note on Wednesday, October 28th. Finally, HC Wainwright reiterated a "buy" rating and set a $16.00 target price on shares of Aclaris Therapeutics in a research report on Wednesday, October 28th. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $11.33.
View Our Latest Research Report on Aclaris Therapeutics
Aclaris Therapeutics Stock Performance
The firm has a fifty day simple moving average of $4.43 and a 200-day simple moving average of $4.53. The company has a market capitalization of $565.44 million, a PE ratio of -6.13 and a beta of 0.96.
Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.04. The business had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.27 million. Aclaris Therapeutics had a negative return on equity of 59.19% and a negative net margin of 1,244.09%. As a group, research analysts anticipate that Aclaris Therapeutics, Inc. will post -0.56 EPS for the current fiscal year.
Institutional Investors Weigh In On Aclaris Therapeutics
Several large investors have recently made changes to their positions in the company. Marshall Wace LLP acquired a new position in shares of Aclaris Therapeutics during the third quarter valued at approximately $3,318,000. Empowered Funds LLC acquired a new stake in Aclaris Therapeutics during the 3rd quarter valued at $243,000. HighVista Strategies LLC acquired a new position in Aclaris Therapeutics during the third quarter valued at $613,000. HighTower Advisors LLC increased its holdings in shares of Aclaris Therapeutics by 3.5% in the 3rd quarter. HighTower Advisors LLC now owns 225,190 shares of the biotechnology company's stock valued at $1,184,000 after purchasing an additional 7,666 shares during the period. Finally, Alps Advisors Inc. grew its position in Aclaris Therapeutics by 37.6% during the third quarter. Alps Advisors Inc. now owns 195,036 shares of the biotechnology company's stock valued at $1,026,000 after purchasing an additional 53,287 shares in the last quarter. Institutional investors and hedge funds own 98.34% of the company's stock.
Aclaris Therapeutics Company Profile
(
Get Free Report)
Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company's development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aclaris Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.
While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.